Publications by authors named "Paz J Vellanki"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

143

Total Likes

64

Extended Reach

88,705

Social Features

33
R
Regulatory implications of ctDNA in immuno-oncology for solid tumors.
Paz J Vellanki, Soma Ghosh, Anand Pathak, Michael J Fusco, Erik W Bloomquist, Shenghui Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A Beaver

J Immunother Cancer· February 2023

Videos about Article: user

1 32 2

View All Article and Social Media Activity
T
The Retrofit: Lessons From Sotorasib's Dosing Conundrum.
Harpreet Singh, Paz J Vellanki, Richard Pazdur

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.
Alexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, Luc Cabel, Lars Dyrskjøt, Paz J Vellanki

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani

Oncologist· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers.
Kristen E Schratz, Diane A Flasch, Christine C Atik, Zoe L Cosner, Amanda L Blackford, Paz J Vellanki

Cancer Cell· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by Mutations.
Paz J Vellanki, Emily A DeBoy, M Malek Bawadkji, Lynn Schuchter, Lisa Rooper

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Erica C Nakajima, Paz J Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S Mishra-Kalyani

Clin Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
Abigail L Koch, Paz J Vellanki, Nicole Drezner, Xiaoxue Li, Pallavi S Mishra-Kalyani

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review.
Paz J Vellanki, Flora Mulkey, Adnan A Jaigirdar, Lisa Rodriguez, Yibo Wang

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis